Breaking News Instant updates and real-time market news.

VRX

Valeant

, ESRX

Express Scripts

$62.90

0.57 (0.91%)

09:28
07/31/17
07/31
09:28
07/31/17
09:28

Express Scripts notes 64 new drug exclusions in 2018 Preferred Formulary

Express Scripts (ESRX) released its 2018 National Preferred Formulary and noted that for the 2018 benefit year, it will introduce 64 new drug exclusions to the NPF. Combined with prior year exclusions, a total of 159 out of 3,791 available drugs will be excluded, Express Scripts said. New exclusions include Amgen's (AMGN) Neupogen, Eli Lilly's (LLY) Forteo and Valeant's (VRX) Wellbutrin SR. Reference Link

VRX

Valeant

ESRX

Express Scripts

$62.90

0.57 (0.91%)

AMGN

Amgen

$174.54

2.39 (1.39%)

LLY

Eli Lilly

  • 08

    Aug

  • 14

    Aug

  • 24

    Aug

  • 11

    Sep

  • 14

    Sep

  • 20

    Sep

  • 21

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

VRX Valeant

07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
ESRX Express Scripts
$62.90

0.57 (0.91%)

06/13/17
WELS
06/13/17
NO CHANGE
Target $83.5
WELS
Outperform
Wells says Mallinckrodt exploring all options, including going private
After hosting CEO Mark Trudeau for an open Q&A session, Wells Fargo analyst David Maris says Mallinckrodt (MNK) continues to look at a range of strategic options to deliver shareholder value, and that all options, including going private, are on the table. Management did an "excellent job" in correcting the record following "erroneous" short-seller presentations, Maris tells investors in a research note. Management detailed Mallinckrodt's relationship with Express Scripts (ESRX) and explained that it is not strained, Maris writes. The analyst notes Trudeau spoke with Express Scripts CEO Timothy Wentworth a week ago about the relationship and that it seems "solid and mutually positive," despite recent negative comments about Acthar from the pharmacy benefit manager's Chief Medical Officer. Maris has an Outperform rating on Mallinckrodt with an $83.50 price target. The stock in premarket trading is up 2% to $42.40 as social media passes around Wells Fargo's comments about the company exploring all options, including going private. As the Wall Street Journal's Charley Grant points out on Twitter, Mallinckrodt said last month at a conference that it is exploring options to drive shareholder value.
06/26/17
COWN
06/26/17
NO CHANGE
Target $17
COWN
Market Perform
Diplomat shares 'overreacting' to potential DIR fee pressure, says Cowen
Cowen analyst Charles Rhyee noted his prior observation following meetings with Express Scripts (ESRX) that the company plans to be more aggressive with DIR fees. However, he estimates a maximum potential downside of $1.36 per Diplomat Pharmacy (DPLO) share in such a scenario, or a bit over 7% of Friday's closing price, making today's pullback an overreaction in his view. He keeps a Market Perform rating and $17 price target on Diplomat shares, which remain down about 8.5% at $16.82 but are well off their earlier lows.
06/27/17
BARD
06/27/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy and entire supply chain have reimbursement risk, says Baird
Baird analyst Eric Coldwell noted Diplomat Pharmacy (DPLO) shares were lower yesterday based on a competitor's research note that suggested Express Scripts (ESRX) was cutting reimbursement in certain commercial plans and is kicking the tires on a DIR rollout in Part D. The analyst believes that would be not only negative for Diplomat but for all in the supply chain. The fact that others were not hit as hard is confusing to Coldwell, but he hopes for clarification from the company's IR day tomorrow. Coldwell maintained his Outperform rating and $20 price target on Diplomat Pharmacy shares.
AMGN Amgen
$174.54

2.39 (1.39%)

07/26/17
OPCO
07/26/17
NO CHANGE
Target $203
OPCO
Outperform
Amgen price target raised to $203 from $189 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Amgen to $203 from $189 after the company reported "strong" Q2 results. The analyst reiterates an Outperform rating on the shares.
07/26/17
BMOC
07/26/17
DOWNGRADE
BMOC
Market Perform
Amgen downgraded to Market Perform from Outperform at BMO Capital
07/18/17
PIPR
07/18/17
NO CHANGE
Target $14
PIPR
Overweight
Piper says Array deal with Amgen 'another example' of successful partnering
Commenting on Array Biopharma's (ARRY) announcement of a preclinical autoimmune partnership deal with Amgen (AMGN), Piper Jaffray analyst Edward Tenthoff called the agreement "yet another example of Array successfully partnering its discoveries" and raising non-dilutive capital. Tenthoff keeps an Overweight rating and $14 price target on Array Biopharma shares.
07/26/17
BMOC
07/26/17
DOWNGRADE
BMOC
Market Perform
Amgen downgraded on valuation lack of near-term catalysts at BMO Capital
As noted earlier, BMO Capital downgraded Amgen to Market Perform from Outperform. Analyst M. Ian Somaiya downgraded the stock based on valuation and his belief that American College of Cardiology guidelines probably won't be updated until late 2018, likely preventing a positive turning point in Repatha sales until 2019. Target $199.
LLY Eli Lilly

07/26/17
LEER
07/26/17
DOWNGRADE
LEER
Market Perform
Eli Lilly downgraded to Market Perform from Outperform at Leerink
07/26/17
07/26/17
DOWNGRADE
Target $90

Market Perform
Eli Lilly downgraded to Market Perform at Leerink
As previously reported, Leerink analyst Seamus Fernandez downgraded Eli Lilly to Market Perform from Outperform, citing intense competition and saying that the regulatory update for Olumiant removes upside optionality in rheumatoid arthritis and possibly other indications given concerns over thrombosis risk. The analyst also lowered his price target on the shares to $90 from $93.
07/26/17
07/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Market Perform from Outperform at BMO Capital. 2. Zoetis (ZTS) downgraded to Hold from Buy at Deutsche Bank with analyst Gregg Gilbert saying the risk/reward is more balanced with the shares up 18% year-to-date. 3. CF Industries (CF) downgraded to Neutral from Outperform at Credit Suisse with analyst Christopher Parkinson citing the recent rally in shares. 4. Eli Lilly (LLY) downgraded to Market Perform from Outperform at Leerink with analyst Seamus Fernandez saying that the regulatory update for Olumiant removes upside optionality in rheumatoid arthritis and possibly other indications given concerns over thrombosis risk. 5. Wynn Resorts (WYNN) was downgraded to Hold from Buy at Union Gaming and to Market Perform from Outperform at Telsey Advisory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/17
COWN
07/25/17
NO CHANGE
Target $95
COWN
Outperform
Eli Lilly delay for baricitinib 'a cloud' over Q2 report, says Cowen
Cowen analyst Steve Scala said that Eli Lilly's Q2 revenue and EPS beat was driven by "solid sales" across most of its key products and he raised his 2017 estimate by a nickel to $4.15 after the company raised its own forecasts for 2017 earnings and sales. However, he called the delay in the resubmission of the NDA for baricitinib for RA a "disappointment" and "a cloud" amid the earnings report. Scala has an Outperform rating and $95 price target on Lilly shares.

TODAY'S FREE FLY STORIES

LOW

Lowe's

$75.82

1.97 (2.67%)

, EV

Eaton Vance

$47.16

0.58 (1.25%)

20:25
08/22/17
08/22
20:25
08/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$75.82

1.97 (2.67%)

EV

Eaton Vance

$47.16

0.58 (1.25%)

AEO

American Eagle

$11.21

0.59 (5.56%)

EXPR

Express

$5.49

0.14 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 11

    Sep

  • 12

    Sep

  • 13

    Sep

  • 14

    Sep

  • 15

    Sep

  • 21

    Nov

T

AT&T

$37.98

0.4 (1.06%)

, TWX

Time Warner

$101.80

-0.31 (-0.30%)

19:14
08/22/17
08/22
19:14
08/22/17
19:14
Hot Stocks
Mexico regulators approve AT&T-Time Warner deal »

The Instituto Federal de…

T

AT&T

$37.98

0.4 (1.06%)

TWX

Time Warner

$101.80

-0.31 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

REGI

Renewable Energy

$11.20

0.1 (0.90%)

18:50
08/22/17
08/22
18:50
08/22/17
18:50
Hot Stocks
Renewable Energy CEO: Commerce Dept. move 'victory' for job creation »

The U.S Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

INTC

Intel

$34.65

-0.27 (-0.77%)

18:37
08/22/17
08/22
18:37
08/22/17
18:37
Hot Stocks
Former Intel CFO Stacy Smith to retire at the end of January, 2018 »

In an email, Intel CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 29

    Aug

COL

Rockwell Collins

$124.29

0.6 (0.49%)

18:36
08/22/17
08/22
18:36
08/22/17
18:36
Upgrade
Rockwell Collins rating change at Vertical Research »

Rockwell Collins upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$92.95

1.19 (1.30%)

18:24
08/22/17
08/22
18:24
08/22/17
18:24
Hot Stocks
Salesforce CEO says closed large deal with Veterans Administration »

Says federal government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

WWR

Westwater Resources

$1.32

-0.14 (-9.59%)

18:16
08/22/17
08/22
18:16
08/22/17
18:16
Hot Stocks
Westwater Resources acquires water rights for Columbus Basin Project in Nevada »

Westwater Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:03
08/22/17
08/22
18:03
08/22/17
18:03
Earnings
Breaking Earnings news story on ZTO Express »

ZTO Express sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:02
08/22/17
08/22
18:02
08/22/17
18:02
Earnings
ZTO Express reports Q2 earnings per ADS 15c, consensus 14c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

URI

United Rentals

$112.44

4.04 (3.73%)

, CMI

Cummins

$153.10

1.04 (0.68%)

17:48
08/22/17
08/22
17:48
08/22/17
17:48
Hot Stocks
United Rentals acquires power equipment assets from Cummins »

United Rentals (URI) has…

URI

United Rentals

$112.44

4.04 (3.73%)

CMI

Cummins

$153.10

1.04 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

, LZB

La-Z-Boy

$31.25

0.1 (0.32%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Maxim Integrated…

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

LZB

La-Z-Boy

$31.25

0.1 (0.32%)

CREE

Cree

$23.03

0.46 (2.04%)

VNET

21Vianet

$4.58

0.03 (0.66%)

CRM

Salesforce

$92.95

1.19 (1.30%)

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

RARE

Ultragenyx

$58.85

1.94 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 23

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

  • 16

    Nov

CRM

Salesforce

$92.95

1.19 (1.30%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
Salesforce says sees FY18 margin up 125-150 bps »

Sees "slight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

17:34
08/22/17
08/22
17:34
08/22/17
17:34
Hot Stocks
Maxim Integrated names Sumeet Gagneja principal accounting officer »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

CTIC

CTI BioPharma

$3.30

0.01 (0.30%)

17:33
08/22/17
08/22
17:33
08/22/17
17:33
Hot Stocks
CTI BioPharma: Chief Business Officer Matthew Plunkett resigns »

Effective August 22,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$47.84

0.51 (1.08%)

17:32
08/22/17
08/22
17:32
08/22/17
17:32
Syndicate
Breaking Syndicate news story on Unum Group »

Unum Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

FTK

Flotek

$5.50

-0.1 (-1.79%)

17:29
08/22/17
08/22
17:29
08/22/17
17:29
Hot Stocks
Flotek announces conclusion of SEC inquiry »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 16

    May

CRM

Salesforce

$92.95

1.19 (1.30%)

17:24
08/22/17
08/22
17:24
08/22/17
17:24
Hot Stocks
Salesforce says 'had best quarter ever' »

Says can reach $20B in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

THO

Thor Industries

$103.90

0.45 (0.43%)

17:17
08/22/17
08/22
17:17
08/22/17
17:17
Hot Stocks
Jayco announces expansion of Middlebury campus, will add 300 jobs »

Jayco, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$924.69

18.03 (1.99%)

, GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

17:14
08/22/17
08/22
17:14
08/22/17
17:14
Hot Stocks
Google introduces Chrome Enterprise »

Google introduced Chrome…

GOOG

Alphabet

$924.69

18.03 (1.99%)

GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

VNET

21Vianet

$4.58

0.03 (0.66%)

17:11
08/22/17
08/22
17:11
08/22/17
17:11
Earnings
21Vianet reports Q2 EPS (12c), one estimate (11c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

17:05
08/22/17
08/22
17:05
08/22/17
17:05
Hot Stocks
root9B Technologies announces incremental funding, status of foreclosure »

root9B Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPT

Gramercy Property Trust

$29.13

-0.03 (-0.10%)

17:03
08/22/17
08/22
17:03
08/22/17
17:03
Hot Stocks
Gramercy Property Trust launches new JV over Class A distribution centers »

Gramercy Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPT

Gramercy Property Trust

$29.13

-0.03 (-0.10%)

17:01
08/22/17
08/22
17:01
08/22/17
17:01
Hot Stocks
Gramercy Property Trust to acquire $479M core logistics portfolio »

Gramercy Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIFI

Boingo Wireless

$19.57

0.32 (1.66%)

16:55
08/22/17
08/22
16:55
08/22/17
16:55
Hot Stocks
Boingo Wireless director Michael Finley sells 7,500 shares »

Boingo Wireless director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

16:55
08/22/17
08/22
16:55
08/22/17
16:55
Hot Stocks
Breaking Hot Stocks news story on root9B Technologies »

root9B Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.